An observational study in Prediabetic State (IGT) and Prediabetic State, sponsored by Sohag University. Not yet recruiting at 1 site in Egypt. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-05.
Sponsored by Sohag University · Observational
the goal of this observation study is to learn about association between intestinal endotoxemia and prediabetes lean patients with the aim of prevention of diabetes in those category of patients
Primary Objective : To determine the correlation between intestinal endotoxemia (measured by serum LBP) and basal beta-cell dysfunction (HOMA-B) in lean prediabetic patients with minimal insulin resistance (HOMA-IR \<1.5).
Secondary Objectives:
Hypothesis:
In lean prediabetes with beta-cell dysfunction (HOMA-IR \<1.5), serum LBP levels correlate significantly with HOMA-B, indicating endotoxemia-driven beta-cell impairment.
999 studies on the registry are indexed under Prediabetic State; 238 are open to participants now.
This study's planned enrollment of 120 is below the median of 216 across 128 observational studies indexed under Prediabetic State.
Browse Prediabetic State studies →Sohag University is the lead sponsor of 1,183 studies on the registry; 612 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The patient population for the trial will be derived from Outpatient clinics, Sohag University Hospital 120 participants .
Exclusion Criteria:
lean prediabetics
Diagnostic Test: hba1c, lbp, fasting blood sugar, lipogram, fastinf insulin
healthy controls
Diagnostic Test: hba1c, lbp, fasting blood sugar, lipogram, fastinf insulin
diagnostic tests for prediabetes and intestinal endotoxemia
correlation between intestinal endotoxemia (measured by serum LBP) and basal beta-cell dysfunction (HOMA-B) in lean prediabetic patients
To determine the correlation between intestinal endotoxemia (measured by serum LBP) and basal beta-cell dysfunction (HOMA-B) in lean prediabetic patients with minimal insulin resistance (HOMA-IR \<1.5).
Time frame: one year
Plan to share: No — to maintain patient confidentialty
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sohag University